Why 'First Come, First Served' Is Also an Ethical Choice — Not a Neutral Default
First come, first served sounds fair in organ allocation. But access to the waiting list itself depends on wealth, geography, and privilege. The race is rigged.
The Illusion of Neutrality
First come, first served sounds fair. But getting on the list at all requires a doctor who refers you, insurance that covers the workup, and a transplant center within driving distance. The race is rigged before it starts.
In 2023, over 104,000 Americans waited for organ transplants, yet only 46,000 received them. The median wait time for a kidney stretched to 3.6 years nationally—but exceeded 7 years in regions like California and New York. Here's the uncomfortable truth: your zip code and tax bracket may determine whether you even enter the queue, let alone survive it.
The Hidden Architecture of Waiting Lists
The "first come, first served" (FCFS) principle appears ethically neutral. It privileges neither the wealthy nor the connected—only those who arrived earliest. But this neutrality collapses under scrutiny because arriving "first" requires overcoming structural barriers that distribute unequally across populations.
The Three Gatekeepers
1. Diagnostic Access
Before joining a transplant waiting list, patients must receive a definitive diagnosis of end-stage organ disease. This requires:
- Regular primary care visits to detect declining organ function
- Specialist referrals for confirmatory testing
- Imaging studies, biopsies, and laboratory panels costing $15,000–$50,000
Uninsured patients present to emergency departments with advanced disease, often after years of undetected progression. By the time they receive a diagnosis, they've already lost months or years of potential waiting time.
A 2019 study in the Journal of the American Society of Nephrology found that uninsured patients initiated dialysis an average of 4.2 months later than insured patients—and started the transplant evaluation process 11.6 months later. First come, first served? Not when some runners begin the race already laps behind.
2. The Referral Cascade
Transplant evaluation requires referral from a nephrologist, cardiologist, or hepatologist to a transplant center. But referral patterns vary dramatically by patient demographics and physician bias.
Research published in Clinical Transplantation (2021) analyzed 89,000 kidney failure patients and found:
- Women were 12% less likely to be referred for transplant evaluation than men with equivalent disease severity
- Black patients experienced 15% lower referral rates compared to white patients
- Patients treated at community hospitals faced 23% lower referral rates than those at academic medical centers
[!INSIGHT] The referral decision—a single physician's judgment—determines whether FCFS even becomes relevant to a patient's survival. This bottleneck concentrates discretionary power in ways that systematically disadvantage already-marginalized populations.
3. Geographic and Economic Constraints
The United States maintains 250+ transplant centers, but they cluster in urban areas and wealthier regions. Rural patients face:
- Average travel distances of 127 miles to nearest transplant center
- Requirement for multiple evaluation visits (typically 3–5 appointments)
- Need for temporary relocation near the center during transplantation and recovery
The economic implications compound. A 2022 analysis estimated that completing transplant evaluation and surgery costs patients $30,000–$75,000 in out-of-pocket expenses (travel, lodging, lost wages, co-pays)—before accounting for post-transplant immunosuppressant medications averaging $12,000 annually.
“*"The allocation of organs is relatively equitable. The allocation of access to the waiting list is not.”
When Neutrality Masks Structural Violence
Philosopher Iris Marion Young's concept of "structural injustice" provides a framework for understanding why FCFS fails as an ethical default. Structural injustice occurs when:
- Large-scale social processes produce systematic disadvantages
- No single agent intends or controls the outcome
- Individuals nonetheless suffer predictable harm
FCFS operates within this structure. It appears neutral because it applies the same rule to everyone. But the rule's outcome depends entirely on starting positions—and those starting positions reflect historical inequities in healthcare access, wealth accumulation, residential segregation, and employment-based insurance.
The Computational Perspective
We can model this mathematically. Let:
- W = waiting time accrued
- T_d = time of disease onset to diagnosis
- T_r = time from diagnosis to transplant referral
- T_e = time for evaluation completion
- T_l = time on official waiting list
Total wait time = T_d + T_r + T_e + T_l
FCFS only considers T_l—time after list enrollment. But the other three terms vary systematically by socioeconomic status:
- Uninsured patients: T_d increases by 0.35–0.5 years (delayed detection)
- Minority patients: T_r increases by 0.8–1.2 years (referral disparities)
- Rural patients: T_e increases by 0.4–0.7 years (logistical barriers)
A Black rural patient without insurance may accumulate 1.5–2.4 years of "invisible waiting time" before the official clock starts. FCFS doesn't ignore this time—it simply erases it from ethical consideration.
[!NOTE] The Organ Procurement and Transplantation Network (OPTN) has implemented some reforms, including broader geographic sharing of organs and reduced weight on waiting time for kidney allocation. However, these adjustments address downstream allocation, not upstream barriers to list enrollment.
Rethinking Allocation Ethics
If FCFS fails as a neutral default, what alternatives exist? Bioethicists have proposed several frameworks:
The Fair Innings Argument: Prioritize younger patients who haven't yet experienced a complete life cycle. This approach acknowledges that older patients have already enjoyed more years of life.
The Benefit Maximization Approach: Allocate organs where they will produce the most quality-adjusted life years (QALYs). This favors younger, healthier recipients with fewer comorbidities.
The Disadvantage Compensation Model: Explicitly adjust priority based on structural barriers faced. A patient who experienced delayed diagnosis due to lack of insurance would receive compensatory points—similar to the way some systems adjust for disease severity.
Each approach has trade-offs. But pretending that FCFS represents ethical neutrality avoids the harder conversation entirely.
Sources: Schold JD et al. (2019). "Access to Kidney Transplantation." Journal of the American Society of Nephrology. Patzer RE et al. (2021). "Disparities in Transplant Referral." Clinical Transplantation. Gentry S. (2022). "Geographic Disparities in Transplant Access." American Journal of Transplantation. OPTN/UNOS Data Reports (2023). Young IM (2011). "Responsibility for Justice." Oxford University Press.
